Conatus Pharmaceuticals (CNAT) Shares Pop Higher on Positive Zika Virus Mention
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
UPDATE - The article notes Zika virus therapies recently published in the journal Nature Medicine.
Conatus has several patents for the liver-disease drug emricasan, which couldbe used as a potential treatment. Some of the patents don't expire until 2028.
Conatus is up 18 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stocks with Implied Volatility Movement
- December volatility at 29 report and outlook
- Options with increasing volume: CMG DAL WDC KMI BA NKE AMD DEPO KMI